Charcot-Marie-Tooth Association Company Profile

04:53 EST 11th December 2018 | BioPortfolio

News Articles [601 Associated News Articles listed on BioPortfolio]

What is Charcot-Marie-Tooth disease? – Metro

MetroWhat is Charcot-Marie-Tooth disease?MetroSeptember is Charcot-Marie-Tooth awareness month. You're forgiven if you have no clue what Charcot-Marie-Tooth disorder is. It's not a well known conditio...

Charcot-Marie-Tooth Experts Launch Organization to Fund Treatments and Cures

NewsTwo Charcot-Marie-Tooth experts have launched a not-for-profit research foundation focused solely on the disease treatments and cures.

Regenacy Pharmaceuticals partners with CMTA to advance ricolinostat for treating hereditary neuropathy

Regenacy Pharmaceuticals, LLC, a clinical-stage biopharmaceutical company developing breakthrough treatments for diabetic and other peripheral neuropathies, today announced a collaboration with the Ch...

FDA fast-tracks Acceleron's Charcot-Marie-Tooth disease candidate

FDA fast-track status was given to Acceleron Pharma's Charcot-Marie-Tooth disease drug candidate ACE-083, which is in midstag -More- 

Acceleron's ACE-083 increases muscle volume in Phase II for Charcot-Marie-Tooth disease

Pharnext planning U.S, EU submissions for Charcot-Marie-Tooth therapy on Phase III data

Pharnext planning U.S., EU submissions for Charcot-Marie-Tooth therapy on Phase III data

$SRPT Announces Agreement with Nationwide Children’s Hospital for Rights to its Gene Therapy Program to Treat Charcot-Marie-Tooth (CMT) Neuropathy, Globally the Most Common Inherited Neuromuscular Disorder

$SRPT Announces Agreement with Nationwide Children’s Hospital for Rights to its Gene Therapy Program to Treat Charcot-Marie-Tooth (CMT) Neuropathy, Globally the Most Common Inherited Neuromuscu...

PubMed Articles [1611 Associated PubMed Articles listed on BioPortfolio]

A role for the GDAP1 gene in the molecular pathogenesis of Charcot‑Marie‑Tooth disease.

In 2002 a series of mutations in the GDAP1 gene were reported in patients suffering from Charcot‑Marie‑Tooth disease manifesting as early-onset, progressive distal‑muscle wasting and weakness. T...

X linked Charcot-Marie-Tooth disease and multiple sclerosis: emerging evidence for an association.

X linked Charcot-Marie-Tooth disease (CMTX) is a hereditary neuropathy caused by mutations in coding for connexin-32, a gap junction protein expressed in Schwann cells, but also found in oligodendroc...

Nerve ultrasound findings differentiate Charcot-Marie-Tooth disease (CMT) 1A from other demyelinating CMTs.

Ulnar/median motor nerve conduction velocity (MNCV) is ≤38 m/s in demyelinating Charcot-Marie-Tooth disease (CMT). Previous nerve high resolution ultrasound (HRUS) studies explored demyelinating C...

MRI of the anterior compartment of the lower leg is a biomarker for weakness, disability and impaired gait in childhood Charcot-Marie-Tooth disease.

Biomarkers of disease severity in Charcot-Marie-Tooth disease (CMT) are required to evaluate early responses to treatment. The study aimed to evaluate the relationship between muscle volume and intram...

Pain in Charcot-Marie-Tooth disease: an update.

Charcot-Marie-Tooth (CMT) disease, the most common inherited peripheral neuropathy, has pain as one of its clinical features, yet it remains underdiagnosed and undertreated. This literature review ass...

Clinical Trials [2192 Associated Clinical Trials listed on BioPortfolio]

Charcot-Marie-Tooth Disease (CMT) Infant Scale (INC-6611)

The purpose of this study is to develop and validate a clinical outcome measure to evaluate disability and disease progression of children 3 years of age and younger (infants and toddlers)...

Effects of Coenzyme Q10 on Charcot-Marie-Tooth Disease

The object of this research is to test the effectiveness of Coenzyme Q10 (CoQ10) on symptoms of weakness, fatigue, and pain in persons with Charcot-Marie-Tooth disease (CMT).In this study ...

Follow up and Observation of Charcot Marie Tooth Disease in Families

The study is aimed to test the hypothesis that there is anticipation in CMT

Study of ACE-083 in Patients With Charcot-Marie-Tooth Disease

This is a multicenter, phase 2 study to evaluate the safety, tolerability, pharmacodynamics (PD), efficacy, and pharmacokinetics (PK) of ACE-083 in patients with CMT1 and CMTX, to be condu...

Assessing Long Term Safety and Tolerability of PXT3003 in Patients With Charcot-Marie-Tooth Disease Type 1A

All randomised patients with Charcot-Marie-Tooth Type 1A (CMT1A) who completed the primary study CLN-PXT3003-02, i.e. 15-month double-blind treatment with PXT3003 or placebo, will be eligi...

Companies [1323 Associated Companies listed on BioPortfolio]

Charcot-Marie-Tooth Association

Hereditary Neuropathy Foundation

Hereditary Neuropathy Foundation (HNF) is a non-profit 501(c)3 organization whose mission is to increase awareness and accurate diagnosis of Charcot-Marie-Tooth disease (CMT) and ...

Pharnext SAS

Pharnext is an advanced clinical stage biopharmaceutical company founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics. P...

Ella Marie Foundation

The Ella Marie Foundation was founded in 1998 with a simple desire of helping others. Over the past 16 years, that mission has expanded into a cohesive effort to enhance the lives...

Marie Claire

More Information about "Charcot-Marie-Tooth Association" on BioPortfolio

We have published hundreds of Charcot-Marie-Tooth Association news stories on BioPortfolio along with dozens of Charcot-Marie-Tooth Association Clinical Trials and PubMed Articles about Charcot-Marie-Tooth Association for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Charcot-Marie-Tooth Association Companies in our database. You can also find out about relevant Charcot-Marie-Tooth Association Drugs and Medications on this site too.

Quick Search


Corporate Database Quicklinks

Searches Linking to this Company Record